MARKET

CEMI

CEMI

Chembio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.520
-0.080
-1.74%
Closed 16:00 11/18 EST
OPEN
4.604
PREV CLOSE
4.600
HIGH
4.690
LOW
4.470
VOLUME
59.17K
TURNOVER
--
52 WEEK HIGH
7.90
52 WEEK LOW
3.950
MARKET CAP
79.40M
P/E (TTM)
-5.8473
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CEMI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CEMI News

  • Edited Transcript of CEMI earnings conference call or presentation 7-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.3d ago
  • Chembio Diagnostics to Participate in Upcoming Investor Conferences
  • GlobeNewswire.4d ago
  • Imagine Owning Chembio Diagnostics (NASDAQ:CEMI) And Wondering If The 35% Share Price Slide Is Justified
  • Simply Wall St..6d ago
  • Chembio Diagnostics, Inc. (CEMI) CEO John Sperzel on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/10 11:59

More

Industry

Pharmaceuticals
+0.06%
Pharmaceuticals & Medical Research
+0.13%

Hot Stocks

Name
Price
%Change

About CEMI

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
More

Webull offers Chembio Diagnostics Inc (CEMI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.